These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Synthesis of novel 1,2-bis-quinolinyl-1,4-naphthoquinones: ERK2 inhibition, cytotoxicity and molecular docking studies. Aly AA; El-Sheref EM; Bakheet MEM; Mourad MAE; Brown AB; Bräse S; Nieger M; Ibrahim MAA Bioorg Chem; 2018 Dec; 81():700-712. PubMed ID: 30268050 [TBL] [Abstract][Full Text] [Related]
24. The protein kinase C-eta isoform induces proliferation in glioblastoma cell lines through an ERK/Elk-1 pathway. Uht RM; Amos S; Martin PM; Riggan AE; Hussaini IM Oncogene; 2007 May; 26(20):2885-93. PubMed ID: 17146445 [TBL] [Abstract][Full Text] [Related]
25. Differential regulation of the phosphoinositide 3-kinase and MAP kinase pathways by hepatocyte growth factor vs. insulin-like growth factor-I in myogenic cells. Halevy O; Cantley LC Exp Cell Res; 2004 Jul; 297(1):224-34. PubMed ID: 15194438 [TBL] [Abstract][Full Text] [Related]
26. Mechanistic Analysis of an Extracellular Signal-Regulated Kinase 2-Interacting Compound that Inhibits Mutant BRAF-Expressing Melanoma Cells by Inducing Oxidative Stress. Martinez R; Huang W; Samadani R; Mackowiak B; Centola G; Chen L; Conlon IL; Hom K; Kane MA; Fletcher S; Shapiro P J Pharmacol Exp Ther; 2021 Jan; 376(1):84-97. PubMed ID: 33109619 [TBL] [Abstract][Full Text] [Related]
27. Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor. Jin F; Gao D; Wu Q; Liu F; Chen Y; Tan C; Jiang Y Bioorg Med Chem; 2013 Sep; 21(18):5694-706. PubMed ID: 23932071 [TBL] [Abstract][Full Text] [Related]
28. Differential targeting of MAP kinases to the ETS-domain transcription factor Elk-1. Yang SH; Whitmarsh AJ; Davis RJ; Sharrocks AD EMBO J; 1998 Mar; 17(6):1740-9. PubMed ID: 9501095 [TBL] [Abstract][Full Text] [Related]
29. Endothelial exposure to hypoxia induces Egr-1 expression involving PKCalpha-mediated Ras/Raf-1/ERK1/2 pathway. Lo LW; Cheng JJ; Chiu JJ; Wung BS; Liu YC; Wang DL J Cell Physiol; 2001 Sep; 188(3):304-12. PubMed ID: 11473356 [TBL] [Abstract][Full Text] [Related]
31. Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation. Gallo A; Cuozzo C; Esposito I; Maggiolini M; Bonofiglio D; Vivacqua A; Garramone M; Weiss C; Bohmann D; Musti AM Oncogene; 2002 Sep; 21(42):6434-45. PubMed ID: 12226747 [TBL] [Abstract][Full Text] [Related]
32. In silico screening and study of novel ERK2 inhibitors using 3D QSAR, docking and molecular dynamics. Larif S; Salem CB; Hmouda H; Bouraoui K J Mol Graph Model; 2014 Sep; 53():1-12. PubMed ID: 25064438 [TBL] [Abstract][Full Text] [Related]
33. Extracellular signal-regulated protein kinase, but not c-Jun N-terminal kinase, is activated by type II gonadotropin-releasing hormone involved in the inhibition of ovarian cancer cell proliferation. Kim KY; Choi KC; Park SH; Auersperg N; Leung PC J Clin Endocrinol Metab; 2005 Mar; 90(3):1670-7. PubMed ID: 15598681 [TBL] [Abstract][Full Text] [Related]
34. Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Péqueux C; Keegan BP; Hagelstein MT; Geenen V; Legros JJ; North WG Endocr Relat Cancer; 2004 Dec; 11(4):871-85. PubMed ID: 15613460 [TBL] [Abstract][Full Text] [Related]
35. Development of extracellular signal-regulated kinase inhibitors. Burkhard K; Smith S; Deshmukh R; MacKerell AD; Shapiro P Curr Top Med Chem; 2009; 9(8):678-89. PubMed ID: 19689374 [TBL] [Abstract][Full Text] [Related]
36. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer. Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694 [TBL] [Abstract][Full Text] [Related]
37. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells. Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520 [TBL] [Abstract][Full Text] [Related]
38. Convergence of MAP kinase pathways on the ternary complex factor Sap-1a. Janknecht R; Hunter T EMBO J; 1997 Apr; 16(7):1620-7. PubMed ID: 9130707 [TBL] [Abstract][Full Text] [Related]
39. A non-catalytic herpesviral protein reconfigures ERK-RSK signaling by targeting kinase docking systems in the host. Alexa A; Sok P; Gross F; Albert K; Kobori E; Póti ÁL; Gógl G; Bento I; Kuang E; Taylor SS; Zhu F; Ciliberto A; Reményi A Nat Commun; 2022 Jan; 13(1):472. PubMed ID: 35078976 [TBL] [Abstract][Full Text] [Related]
40. The anti-apoptotic protein PEA-15 is a tight binding inhibitor of ERK1 and ERK2, which blocks docking interactions at the D-recruitment site. Callaway K; Abramczyk O; Martin L; Dalby KN Biochemistry; 2007 Aug; 46(32):9187-98. PubMed ID: 17658892 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]